Dr. Conry is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
619 19th St S
Birmingham, AL 35233Phone+1 205-934-6600Fax+1 205-978-4346
Education & Training
- University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
- University of Alabama Medical CenterResidency, Internal Medicine, 1987 - 1990
- University of Alabama School of MedicineClass of 1987
Certifications & Licensure
- AL State Medical License 1988 - 2024
- FL State Medical License 2021 - 2023
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Vaccine Therapy in Treating Patients With Melanoma Start of enrollment: 1999 Jan 01
- Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 16
Publications & Presentations
PubMed
- 604 citationsgp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.Douglas J. Schwartzentruber, David H. Lawson, Jon M. Richards, Robert M. Conry, Donald M. Miller
The New England Journal of Medicine. 2011-06-02 - 138 citationsSmoldering myocarditis following immune checkpoint blockadeTimothy G. Norwood, Brian C. Westbrook, Douglas B. Johnson, Silvio H. Litovsky, Nina L.J. Terry
Journal for Immunotherapy of Cancer. 2017-11-21 - 19 citationsComplete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapyS. Marcrom, Jennifer F. De Los Santos, Robert M. Conry
Clinical Sarcoma Research. 2017-07-14
Journal Articles
- E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High Dose Interferon-α2b in Advanced MelanomaArun Nagarajan, Mark R Albertini, Stuart Wong, Noel Laudi, Robert M Conry, Clinical Cancer Research
Press Mentions
- Team of UAB Doctors Performs New Procedure for Rare GI MelanomaMarch 30th, 2021
Grant Support
- Polynucleotide Vaccine Therapy Of Breast CancerNational Cancer Institute2000–2002
- Polynucleotide Vaccine Strategies For MelanomaNational Cancer Institute1999–2002
- Trial Of Antiidiotypic MAB Vaccine 4b5 In MelanomaNational Center For Research Resources2000
- Immunization Of Colorectal Cancer Patients With Oncovax-ClbNational Center For Research Resources2000
- Poylnucleotide Anti Tumor Immunization To Human CEA In Metastic Colorectal CancerNational Center For Research Resources1998–2000
- Alvac Hil2 Intratumorally In Surgically Incurable MelanomaNational Center For Research Resources1998–2000
- Recobinant Vaccinia CEA Delivery In Metastatic CEA Expressing AdenocarcinomaNational Center For Research Resources1998–1999
- Polynucleotide Immunization For Therapy Of Breast CancerNational Cancer Institute1997–1999
- Polynucleotide Vaccines For Colon Cancer And MelanomaNational Cancer Institute1995–1998
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: